Sirolimus as Primary Treatment of Acute Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation  by Pidala, Joseph et al.
BRIEF ARTICLEFrom the
Onco
cer C
Financial d
Correspon
ments
Scien
12902
(emai
Received M
 2009 Am
1083-8791
doi:10.101Sirolimus as Primary Treatment of Acute
Graft-versus-Host Disease following Allogeneic
Hematopoietic Cell Transplantation
Joseph Pidala, Jongphil Kim, Claudio AnasettiGlucocorticoids have gone unchallenged as an essential component of primary therapy for acute graft-ver-
sus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (HCT) despite limited com-
plete response rates and adverse effects from this therapy. The role for alternate immunosuppressive
agents as primary aGHVD treatment remains unexamined. In a series of 10 patients at high risk for cortico-
steroid toxicity or leukemia relapse who developed biopsy-proven grade II-III aGVHD after hematopoietic
cell transplantation, we report that primary therapy with sirolimus resulted in durable complete remission of
aGVHD in 5 (50%) without requirement for glucocorticoids. Mild chronic GVHD (cGVHD) developed in 4
(40%). Projected overall survival (OS) at 18 months is 79% (95% confidence interval [CI]: 38.1%-94.3%), and
projected relapse-free survival (RFS) at 15 months is 70% (95% CI: 32.9%-89.2%). Sirolimus was well toler-
ated with mild and reversible thrombotic microangiopathy occurring in 2 patients. This experience provides
preliminary evidence for the efficacy of sirolimus as a sole primary therapy in the treatment of aGVHD.
Biol Blood Marrow Transplant 15: 881-885 (2009)  2009 American Society for Blood and Marrow TransplantationKEY WORDS: Sirolimus, Acute graft-versus-host disease, GlucocorticoidsINTRODUCTION
Acute graft-versus-host disease (aGVHD) is an im-
portant complication of allogeneic hematopoietic cell
transplantation (HCT). The historic first-line therapy
for aGVHD has included 1-2 mg/kg of prednisone or
equivalent dose of other glucocorticoids. Unfortu-
nately, the complete response (CR) rate to this therapy
isonly30%to40%inseveral published series,withnon-
responders going on to additional immunosuppressive
therapies for steroid-refractory disease [1-8]. Although
previous attempts at combination therapy with addi-
tional agents added to glucocorticoids have produced
mixed results [9,10], early reports from a CTN trialDepartments of Blood and Marrow Transplantation and
logical Sciences, University of South Florida,Moffitt Can-
enter, Tampa, Florida.
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6/j.bbmt.2009.03.020have suggested improved aGHVD response rates to a
regimen of glucocorticoids and mycophenolate mofetil
(MMF) [11]. In published series, overall survival (OS)
for those with steroid responsive disease approaches
50% to 60%, with nonresponders realizingmuchworse
outcomes because of competing threats from refractory
aGVHD, toxicity, cumulative immunosuppression
from additional therapies, primary disease relapse, and
infectious complications. Additionally, up to 70%of pa-
tients will develop chronic GVHD (cGVHD). In the
treatment of aGVHD and cGVHD, patients suffer nu-
merous complications from glucocorticoids.
The primacy of glucocorticoids in the manage-
ment of aGVHD has gone unchallenged. Conversely,
alternative therapies that avoid complications of ste-
roid exposure may offer promise for improved out-
comes. Sirolimus exerts its immunosuppressive effect
through inhibition of mTOR, or mammalian target
of rapamycin, and by downstream effects that include
inhibition of transcription and decreased kinase activ-
ity of cyclin enzymes involved in cell cycle progression;
other postulated effects include inhibition of dendritic
cell development and function, blockade of CD28-
mediated costimulatory signaling on effector T cells,
and a permissive effect on regulatory T cell expansion,
proliferation, and survival [12-15]. Sirolimus has
shown efficacy in the prevention [16,17] and treatment
[18] of aGVHD, but some physicians find intolerable881
Table 1. Baseline Characteristics
Frequency
Median age 57.5 (range: 28-68)
882 Biol Blood Marrow Transplant 15:881-885, 2009J. Pidala et al.the risks of thrombotic microangiopathy (TMA) and
hepatic veno-occlusive disease (VOD) in primary
transplants. Sirolimus has not been examined as
a sole primary therapy for aGVHD.Condition
ALL 1
AML 4
MDS 1
MM 1
MPD 2
NHL 1
Remission status
Complete remission (CR) 2
Not in CR 8
Cell source
PBSCT 10
BMT 0
Donor relation
Related donor 4
Unrelated donor 6
HLA matching
10/10 8
9/10 2
Recipient/donor sex
Female/female 3
Female/male 1
Male/female 1
Male/male 5
Conditioning regimen
Flu/Bu 5
Flu/Bu/ATG 2
Flu/Bu/Rituxan 1
Flu/Mel 1
Pento/BU/Rituxan 1
aGVHD prophylaxis
TAC/MTX 7
TAC/MMF 3
Donor/recipient CMV
Neg/neg 4
Neg/pos 3
Pos/pos 3
aGVHD onset date (median) 3.86 weeks (range: 2.14-14.71)
Overall aGVHD onset grade*
I 0
II 9
III 1
IV 0
aGVHD onset organ stage
Skin
1 2
2 1
3 2METHODS
A series of 10 recipients of HCT who developed
aGVHD were treated with sirolimus as primary ther-
apy; all cases of GVHD were biopsy confirmed. Pri-
mary treatment with glucocorticoids was avoided for
the intolerance in older patients, and sirolimus was se-
lected for its dual activity as immunosuppressant and
anticancer drug for mitigating the exceedingly high
risk for leukemia relapse in patients with active disease
at the time of transplant. In all patients, tacrolimus
target serum levels was decreased to 3-7 ng/mL while
receiving concomitant sirolimus as an attempt to pre-
vent TMA. Sirolimus was administered with a target
serum level of 4-12 ng/mL. In the absence of ongoing
aGVHD, tacrolimus was tapered with empiric dose re-
ductions.
aGVHD was scored weekly per established con-
sensus criteria [19]. CR was defined as sustained com-
plete resolution of aGVHD without recurrence until
death or last follow-up. Partial response was defined
as an overall grade improvement of $1. cGVHD was
scored according to the NIH consensus scoring crite-
ria [20]. Indication, initial dose, and duration of any
glucocorticoid therapy were recorded. Cumulative in-
cidence of disease relapse, cGVHD, cytomegaolvirus
(CMV) reactivation, and TMA are reported. OS, re-
lapse-free survival (RFS), and failure-free survival
were calculated by the Kaplan-Meier method, with
failure defined as nonrelapse mortality (NRM) or re-
quirement of glucocorticoid therapy after initial ther-
apy with sirolimus. This study was approved as
a retrospective review of a nonconsecutive patient
series by the University of South Florida institutional
review board.4 0
GI
1 7
2 1
3 0
4 0
Liver
1 1
2 0
3 0
4 0
ALL indicates acute lymphoblastic leikemia; AML, acutemyelogenous leu-
kemia; MDS, myelodysplastic syndromes; MM, multiple myeloma; MPD,
myeloproliferative disorder; NHL, non-Hodgkin’s lymphoma; aGVHD,
acute graft-versus-host disease; cGVHD, chronic graft-versus-host dis-
ease;GI, gastrointestinal;CMV, cytomegalovirus; PBSCT, peripheral blood
stem cell transplantation; BMT, bone marrow transplantation; Tac/MMF,
tacrolimus/mycophenolate mofetil; Tac/MTX, tacrolimus/methotrexate;
Flu/Mel, fludarabine and melphalan; Flu/Bu, fludarabine and busulfan;
Flu/Bu/ATG, fludarabine, busulfan, and antithymocyte globulin.
*All cases of aGVHD were biopsy confirmed.RESULTS
Ten patients were treated with sirolimus as the pri-
mary therapy for biopsy-proven aGVHD at a median
of 27days afterHCT(range: 15-103days)with primary
aGHVD prophylaxis consisting of either tacrolimus
plus methotrexate (MTX; n 5 7) or MMF (n 5 3).
Medications used in prophylaxis of aGVHD, namely,
tacrolimus and MMF, were continued with sirolimus.
Sirolimus was administered orally, and therapeutic
levels were achieved in all cases, including those with
gastrointestinal (GI) involvement. aGVHD was
treated at the earliest possible time of onset, and there-
forewas grade II overall in 9/10 patients. Baseline char-
acteristics of this series are summarized in Table 1.
Table 2. Summary of Individual Patient Outcomes
Age Disease
Disease remission
at HCT
aGVHD
prophylaxis
Overall onset
grade
Skin/GI/Liver
stage
CR with
Sirolimus
Required
steroids
Malignancy
Relapse Death
28 ALL No Tac/MTX II 2/0/1 Yes No No No
56 MM No Tac/MTX II 0/1/0 Yes No No No
68 AML No Tac/MTX II 0/1/0 Yes No Yes Yes
52 MPD No Tac/MTX II 3/1/0 Yes Yes 0.5 mg/kg (recurrent) No No
58 MPD No Tac/MTX II 1/1/0 No Yes 0.5 mg/kg (persistent) No No
34 NHL No Tac/MTX II 0/1/0 No Yes 0.5 mg/kg (persistent) No No
57 AML Yes Tac/MTX II 3/0/0 No Yes 1 mg/kg and MMF
(persistent)
No No
66 MDS Yes Tac/MMF II 0/1/0 * No Yes Yes
63 AML No Tac/MMF II 0/1/0 Yes No Yes No
67 AML No Tac/MMF III 1/2/0 Yes No Yes No
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; MDS, myelodysplastic syndromes; MM, multiple myeloma; MPD, mye-
loproliferative disorder; NHL, non-Hodgkin lymphoma; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; GI,
gastrointestinal; Tac/MMF, tacrolimus/mycophenolate mofetil; Tac/MTX, tacrolimus/methotrxate; HCT, hematopoietic cell transplant.
*1 mg/kg of prednisone utilized at the onset of aGVHD, but then rapidly tapered off after addition of sirolimus with total duration steroid treatment of 9
days; maintained CR of aGVHD with no further steroids.
Figure 1. Number of patients with weekly overall aGVHD scores after
initiation of sirolimus.
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relapse at timeof transplant,with only 2/10 in complete
remission at the time of transplant. Those not in
remission included secondary acute myelogenous
leukemia (AML) responsive to hypomethylating agents
but with persistent blasts (range: 8%-15%) and cytoge-
netic abnormalities (n5 3), persistent idiopathic mye-
lofibrosis (n 5 2), multiple myeloma (MM) in very
good partial remission (VGPR) with persistent low-
level serum monoclonal protein (n 5 1), follicular cell
lymphoma in partial remission after salvage therapy
with persistent hypermetabolic adenopathy on com-
puted tomography/positron emission tomography
(CT/PET) and no morphologic or molecular bone
marrow involvement (n 5 1), and acute lymphobalstic
leukemia (ALL) s/p induction therapy with morpho-
logic remission, but persistent immunoglobulin gene
rearrangement (n 5 1). At a median follow-up of 6.5
months (range: 2.4-18.3 months), 5 (50%) patients
achieved sustainedCRof aGVHDwith sirolimuswith-
out requiring any second-line therapy with glucocorti-
coids or other salvage therapy (Table 2). In 1 patient,
a complete remission of aGVHD was attained with si-
rolimus, but upon a flare of aGVHD 51 days after ini-
tial remission, a second remissionwas achievedwith the
addition of 0.5mg/kg of prednisone. In 1 patient, 1mg/
kg of prednisone was initially utilized at the onset of
aGVHD, but was rapidly tapered completely off given
concern for toxicity for a total duration of corticoste-
roid therapy of 9 days with the addition of sirolimus; af-
ter complete remission was reached, no further
glucocorticoids were needed. In 3 patients (30%), glu-
cocorticoids were used as salvage therapy after siroli-
mus for persistent aGVHD. Two required 0.5 mg/kg
of prednisone for persistent upper (n 5 1) or lower (n
5 1) symptoms (aGVHD: GI grade 1, overall grade
II); these were similar in baseline characteristics with
those who achieved complete resolution of aGVHD
with sirolimus alone. The other required 1 mg/kg ofprednisone for persistent aGVHD (skin grade 3, over-
all grade II); this case differed in having a DRB1-in-
compatible, 9/10 matched unrelated donor. With
persistent aGVHD after 1 mg/kg of glucocorticoids,
MMF was successful in inducing durable complete re-
mission of aGVHD.Allowing for primary therapywith
sirolimus and salvage steroids, all had reached CR of
aGVHD by 8 weeks after initiation of sirolimus (Fig-
ure 1).
The cumulative incidence of cGVHD in this group
was 40% with maximal cGVHD grade of mild, which
did not require escalation of immunosuppressive ther-
apy. The primary malignancy relapsed in 4 patients.
Two died of recurrent AML, the other 2 patients are
alive after relapse, 1 undergoing therapy and the other
with sustained remission. With a median follow up of
6.5 months (range: 2.4-18.3 months) after transplant,
projected OS at 18 months is 79% (95% CI: 38.1%-
94.3%), and projected RFS at 15 months is 70%
(95% CI: 32.9%-89.2%). Projected failure-free sur-
vival, as defined above, is 51% (95% CI: 16%-78%)
at 18 months after transplant.
884 Biol Blood Marrow Transplant 15:881-885, 2009J. Pidala et al.Sirolimus was overall well tolerated, with 2 cases of
mild TMA that resolved without end-organ compro-
mise after dose reduction (1) or discontinuation (1) of
tacrolimus. By time of death or last follow up, 2 had im-
munosuppression tapered (n5 1) or entirelywithdrawn
(n5 1) for primary disease relapse.None otherwise had
liberated from immunosuppression by median follow-
up of 6.5 months (range: 2.4-18.3 months).DISCUSSION
We report here a series of patients who were
treated with sirolimus as a first-line therapy of biopsy
proven aGVHD. In this group with primarily overall
grade II aGVHD and skin or gut involvement, a CR
rate of 50% was reached with sirolimus alone, which
is comparable to that seen with glucocorticoids. Addi-
tionally, those who required glucocorticoids after pri-
mary treatment with sirolimus achieved CR with only
0.5-1 mg/kg of glucocorticoids, suggesting a potential
steroid-sparing effect. Only 1 patient had aGVHD
refractory to glucocorticoids, which was salvaged
with MMF.
The use of sirolimus as a steroid-free primary ther-
apy for aGVHD in these patients was driven by both
concern for intolerance of steroid adverse effects, but
also that of primary disease relapse after transplanta-
tion. The potential antimalignancy effect of sirolimus
motivated this approach [21-24]. The subjects repre-
sented here largely had high-disease risk, as evidenced
by only 2 of 10 being in complete remission at the time
of transplant. In this setting, the projected 15-month
RFS of 70% compares favorably with what would oth-
erwise be expected, given the high risk nature of these
patients.
Although this limited series provides early evi-
dence to support a clinical trial of this novel approach,
several questions remain. First, the effectiveness of this
approach needs validation in a larger series; selection
bias poses a potential threat to the internal validity of
this retrospective review. Second, sirolimus was suc-
cessful in inducing complete remission of aGVHD in
this series largely comprised of overall grade II disease,
but further work remains to be done to evaluate the
effectiveness of this therapy in more advanced grade
disease. Additionally, although therapeutic levels of si-
rolimus were reached in cases with GI involvement,
more advanced vomiting and/or large volume diarrhea
could preclude achieving consistent therapeutic levels,
as sirolimus is only available as an oral formulation.
Next, although there is a theoretic rationale that siro-
limus may decrease the risk of disease relapse, this
needs to be further examined in sufficiently large
series. Further work also needs to be done to evaluate
this approach in standard risk patients. Finally, al-
though 50% achieved complete remission of aGVHDwithout glucocorticoids here, the magnitude of this
steroid sparing effect would be better borne out with
examination of cumulative burden of steroid exposure
in larger series.ACKNOWLEDGMENTS
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